PFE · Company research
6 upcoming catalysts · 0 phase 2+ trials on file
View Stock opens Yahoo Finance. Prices and performance charts are provided there.
Pfizer expects to report results from its Phase 3 study of mevrometostat (PF-06821497) for 1-2L metastatic castration-resistant prostate cancer post-abiraterone (MEVPRO-1) during 2026 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Berobenatide (PF-3944) 10 Phase 3 obesity studies to start in 2026, expected during 2026 (no exact date yet). A company milestone for Pfizer (berobenatide (PF'3944) for Chronic weight management and obesity comorbidities (knee OA, OSA)): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
PD-1xVEGF (PF'4404) pivotal study starts incl. 1L NSCLC, expected during 2026 (no exact date yet). A company milestone for Pfizer (PF-08634404 (PD-1xVEGF bispecific) for 1L squamous/non-squamous NSCLC and other tumors): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA is expected to decide in Q4 2026 (Oct–Dec) (no exact date yet) whether to approve Pfizer’s TALZENNA (talazoparib) + XTANDI (enzalutamide) for HRR gene-altered metastatic castration-sensitive prostate cancer. Approval clears it for sale in the US; a rejection usually arrives as a letter listing what has to be fixed first.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA is expected to decide in Q4 2026 (Oct–Dec) (no exact date yet) whether to approve Pfizer’s TUKYSA (tucatinib) + trastuzumab + pertuzumab for HER2-positive metastatic breast cancer. Approval clears it for sale in the US; a rejection usually arrives as a letter listing what has to be fixed first.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
35-valent pneumococcal vaccine adult candidate to enter clinic by end of 2026, expected in Q4 2026 (Oct–Dec) (no exact date yet). A company milestone for Pfizer (PCV35 (fifth-generation pneumococcal conjugate vaccine) for Pneumococcal disease, adults): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA’s decision on Pfizer’s Brepocitinib (TYK2/JAK1 inhibitor) for Dermatomyositis was due on Sep 30, 2026. The outcome isn’t recorded here yet — the linked source has the latest.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Pfizer reported results from its Phase 3 study of LITFULO (ritlecitinib) for Nonsegmental vitiligo on Jul 30, 2026. The study met its main goal.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA approved Pfizer’s PADCEV (enfortumab vedotin-ejfv) + pembrolizumab for Muscle-invasive bladder cancer (perioperative) on Jul 10, 2026. The company can now sell it in that market.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Pfizer reported results from its Phase 3 study of sigvotatug vedotin for Previously treated metastatic non-squamous NSCLC on Jun 22, 2026. The study missed its main goal.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA approved Pfizer’s HYMPAVZI (marstacimab-hncq) for Hemophilia A or B, with and without inhibitors on Jun 8, 2026. The company can now sell it in that market.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Pfizer presented data on BRAFTOVI (encorafenib) + cetuximab + chemotherapy for BRAF V600E-mutant metastatic colorectal cancer at a medical meeting on May 31, 2026. The linked source has the details.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Pfizer reported results from its Phase 3 study of ELREXFIO (elranatamab) for Double-class exposed relapsed/refractory multiple myeloma (MagnetisMM-5) on Apr 29, 2026. The study met its main goal.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Pfizer reported results from its Phase 3 study of PF-07307405 (VLA15, with Valneva) for Lyme disease prevention (VALOR) on Mar 23, 2026. The linked source has what the numbers showed.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Pfizer reported results from its Phase 3 study of VLA15 Lyme disease vaccine candidate for Lyme disease prevention on Mar 23, 2026. The study met its main goal.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Pfizer reported results from its Phase 3 study of TALZENNA (talazoparib) + XTANDI (enzalutamide) for HRR gene-mutated metastatic castration-sensitive prostate cancer on Mar 19, 2026. The study met its main goal.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Pfizer reported results from its Phase 2/3 study of Paxlovid for COVID-19 treatment on Nov 5, 2021. The linked source has what the numbers showed.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Pfizer reported results from its Phase 3 study of BNT162b2 (Comirnaty) for COVID-19 prevention on Nov 9, 2020. The linked source has what the numbers showed.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Explore reported politician transactions and public investor statements connected to PFE.
View source-linked activity ↗No phase 2+ trials cached for this company.
No recent headlines on file.